PROCEPT BioRobotics Corp. (PRCT)

In the past six months, PROCEPT BioRobotics' stock price has declined by approximately 30.50%. Key events include strong second-quarter 2025 financial results, the appointment of Larry Wood as CEO, Chicago Capital's acquisition of shares, third-quarter 2025 financial results, presentations at healthcare conferences, a fund cutting its exposure, the stock hitting a new 1-year low, and the scheduling of a Q4 2025 earnings conference call and Investor Day.

PROCEPT BioRobotics' demand seasonality is a recognized factor, with a tool available to identify seasonal patterns. The company's revenue model suggests a potentially more stable demand for consumables once systems are installed, though capital equipment sales might be subject to hospital budgeting cycles.

PROCEPT BioRobotics Corp. is a surgical robotics company focused on urology, specifically treating benign prostatic hyperplasia (BPH). The company's products include the AquaBeam and HYDROS Robotic Systems, which deliver Aquablation therapy, a minimally invasive procedure for removing prostate tissue. The company operates on a razor-and-razor-blade model, selling robotic systems and earning recurring revenue from single-use handpieces.

PROCEPT BioRobotics Corp. is headquartered in San Jose, California. The company has a presence in the United States and internationally, with significant momentum in the United Kingdom. As of September 30, 2025, the installed base of robotic systems in the U.S. was 653.

PROCEPT BioRobotics generally holds a positive brand reputation, driven by its innovative Aquablation therapy and robotic systems. The company has a consensus analyst rating of "Strong Buy" or "Moderate Buy" from various brokerages. Positive aspects contributing to its reputation include clinical validation, technological advancement, market position, reimbursement landscape, and growth prospects. While the stock has underperformed, no specific negative events severely impacting the company's brand reputation in the past year were found.

PROCEPT BioRobotics Corporation's stock is primarily held by institutional investors such as Fmr Llc, Vanguard Group Inc, and BlackRock, Inc. Institutional investors hold a significant portion of the shares, with estimates ranging from approximately 37.63% to 89.46%. Insiders hold about 3.04% to 3.26% of the shares, and retail/other investors hold approximately 15.49% to 43.83%.